Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]

  • In development
  • GID-TA11501
  • Expected publication date: TBC

Please note that following a request from the company, the appraisal is now paused. The committee meeting scheduled for 6 October 2026 will not be going ahead. We expect to provide an update on expected timelines by Q4 2026.

Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early March 2026 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid-May 2026.